Intranasal Oxytocin for Obesity
- PMID: 38815173
- DOI: 10.1056/EVIDoa2300349
Intranasal Oxytocin for Obesity
Abstract
Background: Accumulating preclinical and preliminary translational evidence shows that the hypothalamic peptide oxytocin reduces food intake, increases energy expenditure, and promotes weight loss. It is currently unknown whether oxytocin administration is effective in treating human obesity.
Methods: In this randomized, double-blind, placebo-controlled trial, we randomly assigned adults with obesity 1:1 (stratified by sex and obesity class) to receive intranasal oxytocin (24 IU) or placebo four times daily for 8 weeks. The primary end point was change in body weight (kg) from baseline to week 8. Key secondary end points included change in body composition (total fat mass [g], abdominal visceral adipose tissue [cm2], and liver fat fraction [proportion; range, 0 to 1; higher values indicate a higher proportion of fat]), and resting energy expenditure (kcal/day; adjusted for lean mass) from baseline to week 8 and caloric intake (kcal) at an experimental test meal from baseline to week 6.
Results: Sixty-one participants (54% women; mean age ± standard deviation, 33.6 ± 6.2 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 36.9 ± 4.9) were randomly assigned. There was no difference in body weight change from baseline to week 8 between oxytocin and placebo groups (0.20 vs. 0.26 kg; P=0.934). Oxytocin (vs. placebo) was not associated with beneficial effects on body composition or resting energy expenditure from baseline to week 8 (total fat: difference [95% confidence interval], 196.0 g [-1036 to 1428]; visceral fat: 3.1 cm2 [-11.0 to 17.2]; liver fat: -0.01 [-0.03 to 0.01]; resting energy expenditure: -64.0 kcal/day [-129.3 to 1.4]). Oxytocin compared with placebo was associated with reduced caloric intake at the test meal (-31.4 vs. 120.6 kcal; difference [95% confidence interval], -152.0 kcal [-302.3 to -1.7]). There were no serious adverse events. Incidence and severity of adverse events did not differ between groups.
Conclusions: In this randomized, placebo-controlled trial in adults with obesity, intranasal oxytocin administered four times daily for 8 weeks did not reduce body weight. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov number, NCT03043053.).
Similar articles
-
A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods.Contemp Clin Trials. 2022 Nov;122:106909. doi: 10.1016/j.cct.2022.106909. Epub 2022 Sep 7. Contemp Clin Trials. 2022. PMID: 36087842 Free PMC article. Clinical Trial.
-
Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.Metabolism. 2018 Aug;85:116-125. doi: 10.1016/j.metabol.2018.03.017. Epub 2018 Mar 26. Metabolism. 2018. PMID: 29596853 Free PMC article. Clinical Trial.
-
Oxytocin reduces caloric intake in men.Obesity (Silver Spring). 2015 May;23(5):950-6. doi: 10.1002/oby.21069. Epub 2015 Apr 10. Obesity (Silver Spring). 2015. PMID: 25865294 Free PMC article. Clinical Trial.
-
OXYTOCIN - AN EMERGING TREATMENT FOR OBESITY AND DYSGLYCEMIA: REVIEW OF RANDOMIZED CONTROLLED TRIALS AND COHORT STUDIES.Endocr Pract. 2016 Jul;22(7):885-94. doi: 10.4158/EP151192.RA. Epub 2016 Mar 28. Endocr Pract. 2016. PMID: 27018619 Review.
-
The effects of oxytocin on eating behaviour and metabolism in humans.Nat Rev Endocrinol. 2017 Dec;13(12):700-709. doi: 10.1038/nrendo.2017.115. Epub 2017 Sep 29. Nat Rev Endocrinol. 2017. PMID: 28960210 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical